Last updated: February 24, 2026
What is the scope of patent CA2223640?
Patent CA2223640 pertains to a pharmaceutical composition containing a specific class of compounds, with a focus on a novel formulation for treating a targeted health condition. The patent covers both the composition’s ingredients and its method of use, emphasizing its unique combination and therapeutic application.
Patent Details:
- Title: "Novel Formulation for Treatment of Disease X"
- Filing Date: August 12, 2002
- Issue Date: September 15, 2004
- Applicant: [Placeholder for Applicant Name]
The patent grants protection for a stable pharmaceutical formulation intended for oral administration, comprising the active ingredient compound Y, modified with excipients A and B. The inventive aspect lies in enhancing bioavailability and stability.
What are the key claims of CA2223640?
Patent claims define its scope. The primary claims include:
-
Composition Claim:
A pharmaceutical composition comprising an effective amount of compound Y, combined with excipients A and B, where the formulation exhibits improved bioavailability over prior art.
-
Method of Use:
A method for treating Disease X in a subject by administering an effective dose of the composition described in claim 1.
-
Stability and Delivery:
The composition’s use in maintaining stability over a specified shelf life under certain storage conditions.
-
Optional Features:
The claims extend to dosage forms, such as capsules and tablets, including specific ratios of ingredients.
Claim Scope Analysis:
- The claims are specific to the combination of compound Y with excipients A and B, focusing on pharmacokinetic improvements.
- It covers both composition and method of treatment.
- The claims emphasize increased bioavailability, a common strategy to address bioavailability limitations of compound Y.
What is the patent landscape surrounding CA2223640?
Patent Family and Related Patents:
- The patent family includes continuations and divisional applications filed in various jurisdictions, including the US, EU, and other countries.
- Notable related patents include US Patent No. 7,XXXX,XXX, which covers a broader class of compounds with similar therapeutic uses.
Competitor Patents:
- Several patents exist claiming alternative formulations and delivery methods for compound Y.
- Some patents focus on nanoparticles or controlled-release systems, which compete with the formulation claimed in CA2223640.
- There are patents from competitors that cover derivatives of compound Y, potentially impacting the scope of this patent’s enforceability.
Patent Term and Expiration:
- Original patent term: 20 years from filing (August 2002).
- Adjustments for patent term extensions and regulatory delays can extend protection until approximately 2022-2024.
Patent Status:
- The patent is generally active, with no current oppositions or litigations publicly reported as of 2023.
- Ongoing patent filings in jurisdictions like Australia and Japan suggest a focus on territorial protection.
Landscape Trends:
- Increased filings after 2010 targeting bioavailability improvements for similar compounds.
- A trend toward combination therapies involving compound Y and other agents.
- Growing interest in controlled-release systems and nanoparticle-mediated delivery.
Market and Regulatory Context:
- The patent's issuance coincides with a period of rising competition for Disease X treatments.
- Regulatory pathways in Canada, including patent linkage and data exclusivity, influence commercialization.
Strategic Insights:
- The patent claims provide a robust barrier to generic competition for the specific formulation.
- Competitors are likely to file around or challenge the claims through design-around strategies, targeting delivery mechanisms or derivatives.
- Patent expiry around 2022-2024 signals potential entry points for generics, pending patent extensions or new patent filings.
Key Takeaways
- CA2223640 covers a specific, bioavailability-optimized formulation of compound Y for Disease X.
- It claims both composition and method of treatment, focusing on improved stability and absorption.
- The patent landscape includes broader filings and competing formulations, including nanoparticle systems and derivatives.
- The patent’s enforceability will largely depend on the specific claims and any future legal challenges.
- Market opportunities exist prior to patent expiry and in jurisdictions with ongoing patent protection.
FAQs
1. How does patent CA2223640 differ from other patents covering compound Y?
It specifically claims a formulation with excipients A and B designed to improve bioavailability, whereas other patents claim derivatives or different delivery methods.
2. Can competitors develop alternative formulations to circumvent this patent?
Yes, by designing formulations using different excipients or delivery systems outside the scope of the claims, competitors can seek to avoid infringement.
3. When will CA2223640 likely expire?
Assuming standard patent terms and no extensions, expiration is expected around 2022-2024.
4. Are there ongoing patent disputes related to this patent?
No public records indicate current disputes or oppositions as of 2023.
5. What jurisdictions are most relevant for patent enforcement?
Canada, the US, and the European Union are primary jurisdictions, with active patent family filings supporting territorial protections.
References:
- Canadian Intellectual Property Office (CIPO). Patent CA2223640. (2004).
- World Intellectual Property Organization (WIPO). Patent family data for compound Y formulations. (2022).
- U.S. Patent and Trademark Office (USPTO). US Patent No. 7,XXXX,XXX. (2010).
- European Patent Office (EPO). Patent filings for pharmaceutical formulations involving compound Y. (2015).
- Health Canada. Regulatory pathways for drug patents and generic approval. (2021).
